Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compounds and therapeutical use thereof

a technology of compound and compound, applied in the field of medicinal chemistry, can solve the problems of bone marrow toxicity, cancer cells losing the capacity to undergo cellular suicide, and cancer cells becoming cancerous, and achieve the effect of inhibiting topoisomeras

Inactive Publication Date: 2007-09-06
MYREXIS INC
View PDF99 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0020] The present invention is related to the discovery that 4-arylamino-quinazolines and analogs, as represented in Formula I-VIb below, are potent tubulin inhibitors and active in inhibiting topoisomerase, particularly topoisomerase II. They are activators of the caspase cascade leading to the activation of caspase-3 and inducers or promoters of apoptosis. Thus, they are useful in treating or delaying the onset of diseases and disorders that are responsive to the inhibition of tubulin or topoisomerase, or to the induction of apoptosis.

Problems solved by technology

This makes the cancer cells lose their capacity to undergo cellular suicide and the cells become cancerous.
Thus, a drug like 6-mercaptopurine can cause bone marrow toxicity while remaining ineffective for a slow growing tumor.
It was reported that substitutions on the phenyl ring resulted in reduced activity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds and therapeutical use thereof
  • Compounds and therapeutical use thereof
  • Compounds and therapeutical use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[1275]

(2-Chloro-quinazolin-4-yl)-(4-methoxy-phenyl)-methyl-amine

[1276] a) 2,4-Dichloroquinazoline: A suspension of 2,4-quinazolinedione (5.0 g, 30.8 mmol) in neat phosphorylchloride (50 mL) was heated under reflux for 18 h. The reaction mixture was concentrated under vacuum. The crude product was purified by chromatography (Silica gel) using ethyl acetate and hexane (1:4) to give 2,4-dichloroquinazoline as white solid (4.8 g, 96%). 1H NMR (CDCl3): 8.29 (ddd, J=8.4, 2.1 and 0.9 Hz, 1H), 8.04-8.00 (m, 2H), 7.75 (ddd, J=8.1, 4.8 and 3.0 Hz, 1H).

[1277] b) (2-Chloro-quinazolin-4-yl)-(4-methoxy-phenyl)-methyl-amine: A solution of 2,4-dichloroquinazoline (300 mg, 1.51 mmol) and 4-methoxy-N-methylaniline (248 mg, 1.81 mmol) in 5 ml isopropanol with a drop of concentrated HCl was stirred at room temperature for 8 h. White precipitates were observed in the reaction mixture. The reaction was filtered, and the solid was washed with isopropanol, and dried under vacuum to give white powder (260...

example 2

[1278]

(2-Chloro-quinazolin-4-yl)-(4-methyl-phenyl)-methyl-amine

[1279] The title compound was prepared from 2,4-dichloroquinazoline (250 mg, 1.25 mmol) and 4-methyl-N-methylaniline (196 mg, 1.43 mmol) by a procedure similar to example 1b and was isolated as white powder (210 mg, 84%). 1H NMR (CDCl3): 8.69 (d, J=8.4 Hz, 1H), 7.75 (dd, J=8.1 and 7.5 Hz, 1H), 7.39 (d, J=7.8 Hz, 2H), 7.25 (d, J=7.8 Hz, 2H), 7.13 (d, J=8.2 Hz, 1H), 6.74 (d, J=8.7 Hz, 1H), 3.81 (s, 3H), 2.49 (s, 3H).

example 3

[1280]

(2-Chloro-quinazolin-4-yl)-(4-chloro-phenyl)-methyl-amine

[1281] The title compound was prepared from 2,4-dichloroquinazoline (60 mg, 0.302 mmol) and 4-chloro-N-methylaniline (50 mg, 0.332 mmol) by a procedure similar to example 1b and was isolated as white powder (30 mg, 50%). 1H NMR (CDCl3): 8.66 (d, J=8.4 Hz, 1H), 7.78 (ddd, J=8.1, 7.5 and 2.4 Hz, 1H), 7.57 (d, J=8.7 Hz, 2H), 7.28 (d, J=8.7 Hz, 2H), 7.19 (ddd, J=8.1, 7.5 and 2.4 Hz, 1H), 6.79 (d, J=8.4 Hz, 1H), 3.83 (s, 3H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Description

RELATED U.S. APPLICATIONS [0001] This application is a continuation of Ser. No. 10 / 885,903 filed Jul. 6, 2004, and claims benefit (under 35 U.S.C. § 120) on the earlier filing date of prior U.S. Provisional Application Ser. No. 60 / 484,325 filed Jul. 3, 2003, U.S. Provisional Application Ser. No. 60 / 493,006 filed Aug. 7, 2003, U.S. Provisional Application Ser. No. 60 / 557,556, filed Mar. 29, 2004, and U.S. Provisional Application Ser. No. 60 / 571,288, filed May 14, 2004, the contents of each of which are incorporated herein by reference in their entirety.FIELD OF THE INVENTION [0002] This invention is in the field of medicinal chemistry. In particular, the invention relates to compounds that are activators of caspases and inducers of apoptosis. The invention also relates to the use of these compounds as therapeutically effective anti-cancer agents. TECHNICAL BACKGROUND [0003] Organisms eliminate unwanted cells by a process variously known as regulated cell death, programmed cell death ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/517C07D403/02C07D239/94A61K31/519C07D239/95C07D401/12C07D403/04C07D403/12C07D405/12C07D471/04C07D473/34C07D487/04
CPCC07D239/94C07D239/95C07D401/12C07D403/04C07D487/04C07D405/12C07D471/04C07D473/34C07D403/12A61P29/00A61P31/00A61P31/10A61P31/12A61P35/00A61P37/00A61P37/02A61P37/06A61P43/00A61K31/517
Inventor CAI, SUISIRISOMA, NILANTHAPERVIN, AZRADREWE, JOHNKASIBHATLA, SHAILAJAJIANG, SONGCHUNZHANG, HONGPLEIMAN, CHRISBAICHWAL, VIJAYMANFREDI, JOHNBHOITE, LEENA
Owner MYREXIS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com